Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.

Original languageEnglish (US)
Pages (from-to)1147-1157
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number7
DOIs
StatePublished - May 2010

Fingerprint

Oral Contraceptives
Estradiol
Hemorrhage
Contraceptive Agents
Enzyme Activators
Ethinyl Estradiol
PubMed
Randomized Controlled Trials
Placebos
Clinical Trials
Pharmacology
estradiol valerate-dienogest
Liver
Therapeutics

Keywords

  • Contraception
  • Dienogest
  • Estradiol valerate
  • Heavy menstrual bleeding
  • Menorrhagia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Evaluation of a new estradiol oral contraceptive : Estradiol valerate and dienogest. / Jensen, Jeffrey.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 7, 05.2010, p. 1147-1157.

Research output: Contribution to journalArticle

@article{1566be54f4c341ae815b47c93c02529d,
title = "Evaluation of a new estradiol oral contraceptive: Estradiol valerate and dienogest",
abstract = "Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95{\%} CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.",
keywords = "Contraception, Dienogest, Estradiol valerate, Heavy menstrual bleeding, Menorrhagia",
author = "Jeffrey Jensen",
year = "2010",
month = "5",
doi = "10.1517/14656561003724713",
language = "English (US)",
volume = "11",
pages = "1147--1157",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Evaluation of a new estradiol oral contraceptive

T2 - Estradiol valerate and dienogest

AU - Jensen, Jeffrey

PY - 2010/5

Y1 - 2010/5

N2 - Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.

AB - Importance of the field: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. Areas covered in this review: A historical review of oral contraceptive development leading to the successful design of an estradiol pill. Pharmacology, mechanism of action and clinical trials of contraceptive efficacy and bleeding profile of the estradiol valerate/dienogest (E2V/DNG) pill are reviewed. Details of two placebo-controlled treatment trials of the E2V/DNG pill in women with heavy menstrual bleeding are discussed. All available literature was searched using pubMed and additional data were obtained from published abstracts. What the reader will gain: Information on the novel features and indications for the E2V/DNG pill. Take home message: The dynamic-dosing E2V/DNG oral contraceptive pill provides a highly effective contraceptive option with an adjusted Pearl Index (method failure) of 0.51 (upper limit of 95% CI 0.97) and unadjusted Pearl Index (user failure) of 1.01 (1.59) for women aged 18 - 35 years. In addition, two large randomized controlled trials have demonstrated that E2V/DNG provides effective treatment for women with heavy menstrual bleeding.

KW - Contraception

KW - Dienogest

KW - Estradiol valerate

KW - Heavy menstrual bleeding

KW - Menorrhagia

UR - http://www.scopus.com/inward/record.url?scp=77951287402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951287402&partnerID=8YFLogxK

U2 - 10.1517/14656561003724713

DO - 10.1517/14656561003724713

M3 - Article

C2 - 20367275

AN - SCOPUS:77951287402

VL - 11

SP - 1147

EP - 1157

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -